MEDINCELL S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.66 EUR | +2.10% |
|
+14.05% | +75.83% |
| 04-17 | Medincell: share price rises following agreement with AbbVie | CF |
| 04-16 | Medincell, AbbVie to Co-Develop Injectable Therapeutics | DJ |
| Sales 2024 * | 13.96M 14.93M 20.4M | Sales 2025 * | 41.88M 44.78M 61.22M | Capitalization | 364M 389M 532M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M -24.59M -33.62M | Net income 2025 * | 1M 1.07M 1.46M | EV / Sales 2024 * | 29.6 x |
| Net Debt 2024 * | 48.73M 52.11M 71.23M | Net Debt 2025 * | 58.83M 62.91M 86M | EV / Sales 2025 * | 10.1 x |
| P/E ratio 2024 * |
-13.9
x | P/E ratio 2025 * |
-237
x | Employees | 138 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.98% |
More Fundamentals
* Assessed data
More news
Latest transcript on MedinCell S.A.
More press releases
More news
| 1 day | +2.10% | ||
| 1 week | +14.05% | ||
| Current month | +32.01% | ||
| 1 month | +33.12% | ||
| 3 months | +53.64% | ||
| 6 months | +120.56% | ||
| Current year | +75.83% |
1 week
11.10
12.94
1 month
9.0512.94
Current year
6.9112.94
1 year
5.2512.94
3 years
4.7312.94
5 years
4.3520.00
10 years
4.3520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 03-01-08 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 23-08-31 |
| Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 17-07-04 |
Tone Kvåle
BRD | Director/Board Member | 55 | 22-06-12 |
Virginie Lleu
BRD | Director/Board Member | - | 16-05-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 12.66 | +2.10% | 93,879 |
| 24-04-25 | 12.4 | +2.48% | 121,673 |
| 24-04-24 | 12.1 | -1.47% | 97,316 |
| 24-04-23 | 12.28 | +6.23% | 197,954 |
| 24-04-22 | 11.56 | +4.14% | 138,202 |
Real-time Euronext Paris, April 26, 2024 at 11:37 am
More quotes
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.66
EUR
Average target price
17.15
EUR
Spread / Average Target
+35.47%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +75.83% | 389M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- MEDCL Stock
